---
title: "AbbVie Submits Rinvoq For FDA, EMA Approval In Non-Segmental Vitiligo"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274667977.md"
description: "AbbVie has submitted applications to the FDA and EMA for approval of Rinvoq to treat non-segmental vitiligo in adults and adolescents. The submissions are based on Phase 3 Viti-Up studies, which demonstrated significant improvements in skin repigmentation. Rinvoq is already approved for various immune-mediated inflammatory diseases. AbbVie shares rose 1.18% to close at $225.64 on Monday."
datetime: "2026-02-03T13:54:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274667977.md)
  - [en](https://longbridge.com/en/news/274667977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274667977.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274667977.md) | [繁體中文](https://longbridge.com/zh-HK/news/274667977.md)


# AbbVie Submits Rinvoq For FDA, EMA Approval In Non-Segmental Vitiligo

Add  as your preferred news source on Google

 Add Now

AbbVie (ABBV) on Tuesday said it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of Rinvoq for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV).

The submissions are based on data from the Phase 3 Viti-Up studies, which showed that upadacitinib met the co-primary endpoints of at least 50% improvement in total body repigmentation and at least 75% improvement in facial repigmentation from baseline at week 48.

Rinvoq is a prescription medicine approved for a range of immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis among others.

AbbVie shares closed at $225.64 on Monday, up 1.18%.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [AbbVie Inc. (ABBV.US)](https://longbridge.com/en/quote/ABBV.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Teva receives FDA approval for Prolia biosimilar](https://longbridge.com/en/news/281172040.md)
- [What You Need to Know Ahead of AbbVie’s Earnings Release](https://longbridge.com/en/news/281471479.md)
- [FDA approves new high dose Spinraza regimen for SMA](https://longbridge.com/en/news/281376767.md)
- [AbbVie Dermatology Data Highlights Immunology Depth And Emerging Skin Disease Opportunities](https://longbridge.com/en/news/280880145.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md)